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For the last three decades myocardial perfusion
imaging (MPI) with single photon emission computed
tomography (SPECT) has been an excellent tool for
guiding clinicians in the management of patients with
known or suspected coronary artery disease (CAD).
However, despite its documented high diagnostic accu-
racy1 myocardial perfusion SPECT may fail to detect
the true extent of coronary atherosclerosis and thus
underestimate the coronary risk in individual patients.2
In fact, large observational studies have shown that
43%3 of patients suffering a myocardial infarction and
31%4 of patients dying from a cardiac cause had a
normal or only mildly abnormal prior perfusion scan. A
possible explanation for these shortcomings is inherent
in the nature of the technique. MPI evaluates the
hemodynamic relevance of coronary stenoses and
therefore can only detect obstructive coronary lesions.
However, approximately half of patients with normal
SPECT perfusion have subclinical CAD on coronary CT
angiography (CTA).5 Histopathological correlation
studies demonstrate that almost 70% of coronary
occlusions (leading to myocardial infarction) result from
thrombosis of lesions with a stenosis of less than 50%
before infarction.6 This explains to some extent why—
despite evidence of normal myocardial perfusion—
patients with subclinical CAD are at higher risk of
coronary events, and underlines the importance of
assessing the full (i.e., subclinical) extent of CAD to
guide therapeutic decisions.7
Recent years have witnessed tremendous techno-
logical advances in coronary multislice CTA paralleled
by an increased use of this technology in clinical practice.
Given its high spatial resolution, its noninvasive nature,
its relative ease of use, and its complementary value to
MPI, CTA has been used as an ideal partner modality for
hybrid (or multimodality) imaging with nuclear tech-
niques. Additionally, the increased availability of
dedicated fusion software packages for three-dimensional
coregistration of CTA and MPI have facilitated the use of
hybrid imaging in clinical practice.8,9 The feasibility and
clinical robustness of noninvasive hybrid imaging was
first documented by Namdar and coworkers in a clinical
study involving fusion of 13N-ammonia positron emission
tomography (PET) with 4-slice CTA in 25 patients with
CAD.10 The hybrid PET/CTA images allowed to identify
flow-limiting coronary lesions which required a revas-
cularization procedure (as defined by invasive coronary
angiography and PET) with a sensitivity, specificity,
positive, and negative predictive value of 90%, 98%,
82%, and 99%, respectively. These encouraging results
were confirmed by a similar study with SPECT/CTA
showing that the hybrid approach resulted in a significant
improvement in specificity (from 63% to 95%) and
positive predictive value (from 31% to 77%) compared
to CTA alone for detecting flow-limiting coronary ste-
noses.11 Santana and colleagues showed significantly
higher diagnostic performance for fused SPECT/CT
imaging compared to SPECT alone (P \ 0.001) and to
the side-by-side analysis of SPECT and CT (P = 0.007)
for the diagnosis of obstructive CAD on invasive coro-
nary angiography. Interestingly, this improved diagnostic
performance was mainly a result of a higher sensitivity
in patients with multivessel disease.12 A recent study
implementing motion-frozen SPECT data and CTA-gui-
ded SPECT contour and territory adjustments, found that
the improved diagnostic value of hybrid imaging was
mainly driven by higher diagnostic indices in the left
circumflex (LCX) and right coronary artery (RCA) ter-
ritories.13 Traditionally, LCX and RCA are subject to
more variable patterns of coronary artery anatomy than
the left anterior descending artery, which explains the
particular value of hybrid imaging in these territories.
The study presented in this issue of the Journal of
Nuclear Cardiology by Sato and coworkers14 adds
importantly to previously published studies and fur-
ther underscores the complementary and incremental
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diagnostic value of SPECT and CTA. They report on the
accuracy of combined imaging with 64-slice CTA and
201Thallium SPECT for detecting significant coronary
stenoses on invasive coronary angiography in 130
patients with suspected CAD and an intermediate pretest
likelihood of disease. The analysis was performed on
intention-to-diagnose, considering nonevaluable seg-
ments (14%) on CTA as positive. Compared to CTA
alone, the combined SPECT/CTA analysis resulted in a
significant increase in specificity (from 80% to 92%) and
positive predictive value (from 69% to 85%) without
any change in sensitivity and negative predictive value.
This effect was preserved across all vascular territories
and on a patient-based analysis. These results indicate
that—in line with findings from prior studies—CTA
tends to overestimate coronary stenoses and the com-
bination with SPECT allows identification of many false
positive CTA findings. Specificity and positive predic-
tive value are particularly suboptimal in the presence of
motion artifacts or severe coronary calcifications. In
their study, Sato and colleagues were also able to shed
some light on the distribution of perfusion defects
among nonevaluable coronary arteries. Interestingly,
perfusion defects were rarely observed in vessels with
motion artifacts, but were more frequent in severely
calcified vessels (59%). Thus, a severely calcified
nonevaluable segment should prompt further testing due
to its relatively high likelihood of obstructive disease,
whereas segments (particularly in the RCA territory)
with motion artifacts are usually rather ‘‘benign’’.
Sato and colleagues, together with previously pub-
lished data, provide a basis to guide our choice of
diagnostic tests in patients with suspected CAD with an
intermediate pretest probability of disease. In patients in
the lower spectrum of intermediate probability, CTA
may be the preferred test due to its high negative pre-
dictive value (97% in the study by Sato et al) and lower
prevalence of disease in this group of patients. In the
presence of equivocal CTA findings or nonevaluable
findings, MPI may detect hemodynamically relevant
CTA lesions or identify obstructive lesions requiring
revascularisation. In patients with an intermediate-to-
high pretest probability, the likelihood of coronary cal-
cifications is higher and a lower positive predictive
value of CTA can be anticipated. Therefore, MPI may
be considered a better first-line test. CTA can be added
in the presence of equivocal MPI findings suggestive of
attenuation artifacts or microvascular disease.15 Of note,
a combined SPECT/CTA approach is most useful in
patients where the initial diagnostic test yields equivocal
findings but should not be used routinely in all patients
with suspected CAD. Thus, the most practical approach
for clinical effectiveness and minimization of costs and
radiation dose is sequential scanning (as practiced by
Sato et al) with the preferred imaging modality first and
a complementary test added if required for clinical
diagnosis and decision-making.
An important limitation commonly encountered in
studies assessing the value of hybrid imaging is the lack
of an appropriate gold standard, to which noninvasive
hybrid imaging could be compared. As shown before,
the findings from angiographic techniques differ very
often from perfusion findings by SPECT.16 Therefore,
the simple angiographic stenosis (albeit accurately
measured with quantitative coronary angiography by
Sato et al) is probably a poor standard to reflect the
pathophysiologic and prognostic severity of CAD. This
is why, to a certain extent, disagreement between
SPECT/CTA and coronary angiography is unavoidable
by nature of the tests used. For instance, if a 60% ste-
nosis is correctly identified by CTA and coronary
angiography, this will result in agreement between both
techniques. However, if the lesion is not associated with
a perfusion defect on SPECT, the combined SPECT/
CTA analysis will classify this lesion as a ‘‘false neg-
ative’’ finding which will contribute to reducing the
diagnostic accuracy of the combined technique. This
apparent disagreement occurs because this particular
60% stenosis is not flow-limiting, a feature that is not
assessed by quantitative coronary angiography.
Finally, the added radiation dose from nuclear
Imaging techniques and CT is an important issue lim-
iting its clinical use. In the study by Sato et al the total
radiation dose from helical CTA (without tube current
modulation) and 201Thallium SPECT exceeded 30 mSv.
However, implementation of modern CT acquisition
protocols such as prospective ECG-triggering17 and
body mass adapted tube voltage and current modula-
tion18 allows reduction of the radiation dose from CTA
by 60-80%. Additionally, SPECT perfusion tracers with
shorter physical half-lives (99mTc-tetrofosmin or 99mTc-
sestamibi) are associated with lower radiation doses than
201Thallium. A recent study with stress-only hybrid
SPECT/CTA imaging reported a total radiation dose of
5.4 mSv for a combined study.19
The role of percutaneous coronary interventions
(PCI) in patients with stable CAD remains a contro-
versial issue, and it is a recognized fact, that stent
implantations represent a key cost driver in modern
cardiological practice. The current evidence from pub-
lished trials emphasizes that, in patients with stable
CAD and preserved left ventricular function, PCI fails to
offer any prognostic benefit over optimal medical ther-
apy, unless a significant amount (generally more than
10%) of the left ventricular myocardium is ische-
mic.20,21 In this case PCI might be more effective than
medical therapy in reducing the ischemic burden and
thereby improving the patients’ prognosis.22 However,
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in some patients, it may be challenging to identify the
culprit lesion from the side-by-side evaluation of MPI
and angiography (either CT or invasive). This may
contribute to stent overuse to avoid ‘‘missing’’ any
significant stenosis. The combination of MPI and CTA
into a three-dimensional hybrid image allows the
superimposition of myocardial territories onto their
subtending coronary arteries, thereby reliably identify-
ing the culprit lesion requiring revascularization. In a
previous report of 38 patients with perfusion defects on
SPECT, the number of lesions with equivocal hemody-
namic relevance was significantly reduced with SPECT/
CTA fusion compared to the side-by-side analysis.9 This
comprehensive noninvasive approach might help to
avoid PCI in nonobstructive lesions, thereby reducing
stent overuse, cutting on healthcare costs and preventing
excess coronary events.23
Cardiac multimodality imaging is a new and highly
dynamic field of continuing research driven by the con-
stant technological advances and innovation of non-
invasive imaging and the increasing clinical interest. Its
impact extends beyond its clinical utility onto the orga-
nization of diagnostic healthcare structures. Traditionally,
the different diagnostic tests in CAD diagnosis (i.e., CTA,
MPI, and invasive coronary angiography) have been
firmly in the hands of different medical specialities, such
as radiology, nuclear medicine, and cardiology. However,
it is foreseeable that the appropriate use of alternative and
complementary tests will require their integration into
joint clinical diagnostic services where experts in all
methods collaborate (Figure 1).24 Colleagues with clini-
cal and technical expertise together can exploit the
potential of new techniques for studying both anatomy
and pathophysiology. This process will be supported by a
shift from specializing in a particular technique that is
applied by cross-sectional imaging to multiple organs, to
an organ or system-based approach where the diagnostic
expert is more concerned with function, the integration of
results into clinical decision-making, and the impact of
diagnostic imaging on clinical outcomes.24
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